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Abstract
Background: In patients with type 1 diabetes mellitus (T1DM), cardiovascular events are more common, and the
outcome following a myocardial infarction is worse than in nondiabetic subjects. Ischemic or pharmacological
preconditioning are powerful interventions to reduce ischemia reperfusion (IR)-injury. However, animal studies have
shown that the presence of T1DM can limit these protective effects. Therefore, we aimed to study the protective effect
of ischemic preconditioning in patients with T1DM, and to explore the role of plasma insulin and glucose on this effect.
Methods: 99mTechnetium-annexin A5 scintigraphy was used to detect IR-injury. IR-injury was induced by unilateral
forearm ischemic exercise. At reperfusion, Tc-annexin A5 was administered, and IR-injury was expressed as the
percentage difference in radioactivity in the thenar muscle between the experimental and control arm 4 hours after
reperfusion. 15 patients with T1DM were compared to 21 nondiabetic controls. The patients were studied twice, with
or without ischemic preconditioning (10 minutes of forearm ischemia and reperfusion). Patients were studied in either
normoglycemic hyperinsulinemic conditions (n= 8) or during hyperglycemic normoinsulinemia (n= 7). The controls
were studied once either with (n= 8) or without (n= 13) ischemic preconditioning.
Results: Patients with diabetes were less vulnerable to IR-injury than nondiabetic healthy controls (12.8 ± 2.4 and
11.0 ± 5.1% versus 27.5 ± 4.5% in controls; p < 0.05). The efficacy of ischemic preconditioning to reduce IR-injury,
however, was lower in the patients and was even completely abolished during hyperglycemia.
Conclusions: Patients with T1DM are more tolerant to forearm IR than healthy controls in our experimental model. The
efficacy of ischemic preconditioning to limit IR-injury, however, is reduced by acute hyperglycemia.
Trial Registration: The study is registered at www.clinicaltrials.gov (NCT00184821)
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Background
Type 1 diabetes mellitus (T1DM) substantially increases
the risk for ischemic heart disease, including acute myo-
cardial infarction [1]. In addition, the mortality rate in
various clinical settings of ischemia-reperfusion (IR) in-
jury, including acute myocardial infarction [2,3], and
coronary artery bypass grafting [4,5], is higher in
patients with diabetes mellitus, both in type 1 and in
type 2 diabetic patients. Also, the incidence of heart fail-
ure is increased in patients with T1DM, and is directly
associated with the glycated hemoglobin A1c (HbA1c)
concentration [6]. Therefore, novel therapies to reduce
IR-injury and improve prognosis in patients with T1DM
are urgently needed.
The most powerful intervention to limit myocardial
infarct size, other than early coronary reperfusion, is is-
chemic preconditioning, which is defined as a reduction
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in infarct size by a preceding short period of myocardial is-
chemia [7]. Based on this principle, alternative cardiopro-
tective strategies have been developed, including remote
preconditioning and pharmacological preconditioning [8].
These interventions not only protect the heart against IR
injury, but also other tissues including the kidney, the
brain, the liver, and skeletal muscle. Unfortunately, it has
been shown in animal models of myocardial infarction that
various comorbidities, including hypercholesterolemia and
diabetes, can limit the efficacy of these cardioprotective
interventions [9]. In animal models of T1DM, studies on
the effect of ischemic preconditioning on myocardial in-
farct size have yielded contradicting results [10].
In humans, the impact of T1DM on IR-injury and is-
chemic preconditioning has never been studied in vivo.
Therefore, in the current study, we aimed to answer
three research questions: 1) does T1DM affect the toler-
ance for IR?; 2) does T1DM modulate the protective ef-
fect of ischemic preconditioning?; and 3) is the effect of
T1DM on these parameters dependent on the plasma
glucose and insulin concentrations?
To this end, 99mtechnetium annexin A5 scintigraphy
was used as a well-validated model of forearm IR-injury
[11-15]. This model is based on the fact that early after
reperfusion phosphotidylserin residues are exposed on
the outer membrane leaflet of affected cells, as an early
marker for cellular damage [16]. Annexin A5 binds with
a high affinity to these residues. By labeling recombinant
human annexin A5 to 99mTc, these changes can be
detected in humans in vivo as a marker for IR-injury.
Materials and methods
Ethics statement
The protocol has been approved by the Institutional Re-
view Board of the Radboud University Nijmegen Medical
Centre, and the study was performed in compliance with
the recommendations of the Declaration of Helsinki. All
patients signed for informed consent before participa-
tion. The study is registered at www.clinicaltrials.gov
(NCT00184821).
Subjects and experimental conditions
Fifteen male patients (aged>18 years) with uncomplicated
T1DM (defined as the absence of pancreatic beta cell re-
serve as reflected by a low plasma C-peptide) participated.
Patients with hypertension (supine blood pressure >140/
90 mmHg), diabetic retinopathy, (micro) albuminuria or
cardiovascular disease were excluded. All subjects were
studied after an overnight fast and 24 hours of caffeine
abstinence.
The patients were randomized to either a normal glu-
cose/high insulin group (n = 8) and high glucose/normal
insulin group (n = 7). All patients lowered their evening
dose of insulin dose by 30% at the night before the
experimental days and skipped the morning dose of in-
sulin to compensate for their fasting state. In eight
patients, on the days of the experiments, blood glucose
was tightly controlled between 4 and 8 mmol/l until the
start of ischemia, using intravenous insulin when
needed. In the remaining 7 patients, blood glucose was
kept above 15 mmol/l at the start of ischemia, using
intravenous glucose when needed. After one hour of
reperfusion, all patients were allowed to have lunch and
to use their normal insulin regimen. The results from
these patients were compared with a control group of 21
healthy male subjects, who have been described in a pre-
vious study [11].
Experimental protocol
All patients with T1DM were studied twice in a crossover
design, with an interval of at least one week in between
the experiments. In random order, each patient was sub-
jected to the ischemic exercise protocol alone or to ische-
mic preconditioning followed by ischemic exercise. The
healthy volunteers were subjected to either ischemic exer-
cise alone (n= 13) or to ischemic preconditioning followed
by ischemic exercise (n= 8).
In the ischemic exercise protocol, after cannulation of
an antecubital vein of the dominant forearm, maximal vol-
untary contraction was determined in the non-dominant
arm with a handgrip dynamometer (Baseline Hydrolic
Hand Dynamometer, Fabrication Enterprise Inc., Irvington,
New York, USA). Subsequently, the circulation of the non-
dominant arm was occluded for 10 minutes by inflation of
an upper arm cuff to 200 mmHg. Simultaneously, the sub-
jects performed rhythmic isometric hand gripping exercise
at 50% of maximal voluntary contraction for 5 seconds
every 10-second period until exhaustion. The total dur-
ation of ischemia was 10 minutes. Immediately upon
reperfusion, 0.1 mg of hydrazinonicotinamide (HYNIC)-
derivatized recombinant human annexin A5, radiolabeled
with 450 MBq Tc-99 m, was administered intravenously
(5 mSv). Both hands were imaged at 4 hours after injection
with a gamma camera (Siemens Orbiter, Hoffman Estates,
Illinois, USA, equipped with low- energy high resolution
collimators) connected to a Hermes Gold image proces-
sing system (Nuclear Diagnostics, Stockholm, Sweden) as
previously described [11].
In the ischemic preconditioning experiments, the 10
minutes of ischemic exercise were preceded by 10 minutes
of forearm ischemia (without concomitant handgripping)
and 10 minutes of reperfusion.
Preparation of 99mTc-HYNIC-annexin A5
Radiolabeled annexin A5 was freshly prepared before each
experiment by adding 99mTc-pertechnetate (1500 MBq) in
the presence of stannous tricine to succinimidylhydrazino-
nicotinamide (HYNIC)-conjugated recombinant human
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annexin A5 (NAS 2020, 0.275 mg per vial; Theseus Im-
aging Corp). For the patients with diabetes who were stud-
ied during hyperglycemia, recombinant human annexin
A5 (obtained from Theseus Imaging Corporation) was
conjugated with HYNIC in our own laboratory. The radi-
olabeling procedure of this HYNIC-conjugated annexin
A5 was identical to that of NAS 2020.
Analytical procedures
Plasma caffeine concentrations were determined by use
of reversed-phase HPLC with UV detection set at
273 nm according to Schreiber-Deturmeny and Bruguerolle
[17]. Insulin was measured by direct radioimmuno-
assay (RIA) using an International Standard for
human Insulin (NIBSC code 83/500). The intra assay
coefficient of variation (CV) was 5.6%, 6.6% and 6.7%
at insulin concentrations of 20.5, 41.5, and 56.8 mE/L
and the inter assay CVs at these concentrations were
9.8%, 10.0% and 13.6%. C-peptide was measured with
a Double Antibody kit obtained from DPC (DPC
Nederland B.V., Breda, the Netherlands).
Data analysis and statistics
All the digitized gamma camera images were analyzed
offline by the same investigator who was unaware of the
experimental conditions (WJGO) using Hermes software
(Hermes Gold, Nuclear Diagnostics, Stockholm, Sweden).
Fixed-size circular regions of interest (ROI) were drawn
over the thenar muscle of both hands. Special care was
taken to avoid the major arteries and veins in the ROI. To
correct for background activity, the final result was
expressed as the percentage difference between the
Annexin A5 uptake in the ROIs of the experimental hand
and control hand (‘targeting’).
All results are expressed as mean ± SEM unless
indicated otherwise. Between-group differences were
assessed using a one-way ANOVA of variance, followed
by unpaired t-tests to identify significant contrasts.
In the diabetes patients, the effect of ischemic precon-
ditioning was analysed using a paired t-test. The effect
of glycemic control during the experiment on the effi-
cacy of ischemic preconditioning was statistically ana-
lyzed using a repeated measures ANOVA with ischemic
preconditioning as a within-subject factor and the ex-
perimental condition as a between subject factor. Pos-
sible confounding by age was explored by determining
the effect of the inclusion of age as a covariate in this
statistical analysis. A two-sided p value <0.05 was con-
sidered to indicate statistical significance (SPSS for Win-
dows, release 12.0.1).
Results
Baseline characteristics of the study groups are summar-
ized in Table 1. The plasma caffeine concentration was
less than 0.5 mg/l in all subjects, indicating good com-
pliance with caffeine abstinence. The plasma C-peptide
concentration was≤ 0.05 nmol/l in all diabetic patients,
confirming a type 1 diabetes.
Metabolic control during the experiment
As intended, the two groups of patients with diabetes
significantly differed with respect to plasma insulin and
glucose concentrations (see Table 1). Remarkably, in the
patients who did not receive intravenous insulin treat-
ment prior to ischemic exercise, the plasma insulin con-
centration did not significantly differ from the levels
observed in the healthy volunteers.
The difference in plasma glucose concentration between
the normoglycemic and hyperglycemic non-preconditioned
diabetes groups persisted throughout the reperfusion
period: 6.8± 1.9 (SD; n=8) versus 16.4± 2.3 mmol/l (n= 7)
at 1 hour and 11.6±3.5 (n=8) versus 19.3± 1.6 mmol/l
(n=7) at four hours after reperfusion for the group with
and without extra insulin, respectively (p <0.005 at both
time points). After ischemic preconditioning followed by is-
chemic exercise, similar results were obtained: 6.8± 1.8
(n=8) versus 19.0±4.1 mmol/l (n= 7) at one hour and
12.5± 1.7 (n=8) versus 22.2± 4.1 mmol/l (n=7) at four
hours after reperfusion (p <0.001 at both time points).
Annexin A5 targeting after ischemic exercise
Independent of the metabolic control during the experi-
ment, annexin A5 targeting after ischemic exercise was
lower in patients with T1DM than in healthy volunteers
(12.8 ± 2.4 (SEM; n = 8) and 11.0 ± 5.1% (n = 7) in the two
groups of patients with diabetes versus 27.5 ± 4.5%
(n = 13) in the healthy controls; p < 0.05 for diabetes ver-
sus control; Figure 1). Ischemic preconditioning tended
to reduce targeting in the patients with normal glucose/
high insulin without reaching statistical significance
(12.8 ± 2.4 versus 8.4 ± 1.8%; p = 0.087; n = 8). In the
patients who were studied under hyperglycemic condi-
tions, ischemic preconditioning did not limit targeting
(11.0 ± 5.1 versus 15.9 ± 7.9% in absence and presence
of ischemic preconditioning, respectively; p = 0.20;
n = 7). Within the tested population of patients with
diabetes, the protective effect of ischemic precondi-
tioning was significantly higher in those who were
studied under normoglycemic hyperinsulinemic condi-
tions as compared with those who were studied during
hyperglycemia (repeated measures ANOVA: significant
interaction between the effect of ischemic precondi-
tioning and experimental condition (p = 0.035 and
p = 0.025 without and with age as a covariate respect-
ively); Figure 2). In contrast to the patients with dia-
betes, the healthy volunteers showed a profound and
consistent reduction in annexin targeting by ischemic
preconditioning (Figure 1).
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Discussion
The current study is the first to investigate in humans
in vivo whether T1DM affects the tolerance for IR and the
protection by ischemic preconditioning. Patients with
T1DM appear to be more resistant to IR in the forearm
skeletal muscle. The efficacy of ischemic preconditioniong
to limit IR-injury, however, is lower in patients with
diabetes than in nondiabetic control subjects, and is even
completely abolished during hyperglycemia.
Despite optimal reperfusion therapy, morbidity and
mortality in patients suffering an acute myocardial
infarction remain significant [18]. Therefore, novel strat-
egies to limit IR-injury are warranted. Based on the find-
ing that ischemic preconditioning profoundly reduces
myocardial infarct size, several novel treatment modal-
ities have recently been developed and tested in humans,
including remote preconditioniong [19], and pharmaco-
logical preconditioning [8]. For patients with diabetes,
this need for additional treatment is even more urgent,
given the fact that the risk of cardiovascular events is
Table 1 Baseline characteristics of the subjects
T1DM; normal glucose T1DM; high glucose Healthy volunteers
without IP
Healthy volunteers
with IP
N 8 7 13 8
Age (years) 28 ± 8 35 ± 11* 22 ± 3{ 24 ± 4{
Body mass (kg) 78 ± 10 76 ± 8 74± 9 82± 7
Height (cm) 182± 7 178 ± 4 180 ± 7 185± 4
Systolic blood pressure (mmHg) 129± 9 124 ± 6 127 ± 7 131± 7
Diastolic blood pressure (mmHg) 78 ± 5 73 ± 8 75± 10 66 ± 10
Heart Rate (bpm) 72 ± 8 65 ± 6 68± 10 68 ± 14
HbA1c (%) 7.6 ± 0.9 8.2 ± 0.9 - -
Plasma glucose at onset of ischemic
exercise (mmol/l)
- IP{ 6.3 ± 1.2*{ 18.2 ± 1.5*{ 4.5 ± 0.6{
+ IP{ 6.4 ± 0.8{ 19.4 ± 2.0{ - 5.0 ± 1.1{
Plasma insuline at onset of ischemic
exercise (mU/l)
- IP{ 43.9 ± 27.6*{ 10.6 ± 4.2{ 14 ± 8{ -
+ IP 28.3 ± 26.3 9.9 ± 4.2 - -
Maximal voluntary contraction (kg) 49 ± 7{† 40 ± 6{ 42 ± 9† 62 ± 12*{
Values are means ± SD. *: p < 0.05 versus healthy controls without IP. †:p < 0.05 versus healthy controls with IP. {:p < 0.05 versus T1DM with high glucose.
Figure 1 Targeting of annexin A5 to the thenar muscle after
ischemic exercise at four hours after reperfusion in the absence
(open bars) and presence (black bars) of ischemic
preconditioning. *: p < 0.05 versus healthy volunteers without
ischemic preconditioning.
Figure 2 Effect of ischemic preconditioning on annexin A5
targeting in the two experimental conditions in patients with
diabetes (normal glucose and high glucose). Δ targeting was
calculated as the targeting after ischemic exercise with
preconditioning minus targeting after ischemic exercise without
preconditioning.
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higher, and the mortality rate following a cardiovascular
event is increased, both in type 1 and in type 2 diabetic
patients [2,3]. In addition, the incidence of heart failure
is higher in patients with T1DM [6]. There are several
potential explanations for this worse outcome following
infarction in patients with diabetes. In diabetic patients
suffering from a myocardial infarction, infarct size (esti-
mated with nuclear imaging) is larger than in nondia-
betic patients, both after thrombolysis and after primary
percutaneous coronary intervention [20,21]. It was sug-
gested, however, that the small difference in infarct size
could not completely account for the 4–6 fold increased
mortality in the diabetic patients in this study [21]. This
was recently confirmed in an animal study, in which the
mortality rate following a myocardial infarction was higher
in diabetic rats than in control rats, despite similar infarct
size. It was speculated that autonomic dysfunction in the
diabetic rats contributes to this increased mortality [22].
Despite the clinical observations that suggest that
patients with diabetes are more susceptible to myocar-
dial IR-injury, animal studies have provided conflicting
results. A vast amount of studies have explored the tol-
erance of myocardial tissue for IR in animal models
of type 1 and type 2 diabetes mellitus [9,10,23-27]. Al-
though some studies have reported that the myocardium
is more resistant to IR-injury in animals with T1DM,
other studies have found either no effect, or an increased
susceptibility. Probably, this tolerance to IR is dependent
on the duration of diabetes (an increased resistance has
been reported in particular early after the onset of dia-
betes), the animal species, and the duration of IR [10].
In addition, it has to be taken into account that the ani-
mal models of T1DM do not accurately reflect the
human pathology of diabetes in all aspects (e.g. the tox-
ins administered to destruct the pancreas might have al-
ternative mechanisms of action, and do not reflect the
auto-immune destruction that occurs in humans).
Experiments in animal models of myocardial infarction
have demonstrated that comorbidities, including dia-
betes, myocardial hypertrophy, and hypercholesterolemia
can limit the protective effect of (ischemic) precondi-
tioning [9]. Several animal studies have investigated
whether the diabetic heart is still amenable to the cardi-
oprotective effect of (ischemic) preconditioning. Most
studies in animal models of T1DM (mainly diabetes
induced by the administration of streptozotocin) have
demonstrated that the cardioprotective effect of ische-
mic preconditioning is abolished [28,29]. Also, acute
hyperglycemia completely abolished the infarct size-
limiting effect of ischemic precondioning [30]. In Goto-
Kakizaki diabetic rats, the cardioprotective effect of pre-
conditioning could be restored, however, by increasing
the intensity of the preconditioning stimulus, illustrating
that diabetes increases the threshold for preconditioning
[31]. It has been suggested that the diminished potential
for cardioprotection in diabetes is due to impaired func-
tion of the ATP-dependent potassium channel (KATP-
channel), or due to decreased phosphorylation of im-
portant signalling kinases including Akt and glycogen
synthase kinase (GSK)-3β [10,26].
These findings of a reduced efficacy of ischemic pre-
conditioning have been confirmed in experimental stud-
ies on IR-injury in human atrial trabeculae: in patients
with diabetes, the cardioprotective effect of ischemic
preconditioning was either abolished, or the threshold
for cardioprotection was increased, possibly due to
impaired opening of KATP-channels [32-34].
In our study, annexin A5 targeting after forearm IR
was lower in patients with T1DM than in nondiabetic
control subjects, indicating an increased resistance to IR.
We postulate that this is, at least in part, due to the pro-
tective effect of insulin against IR-injury. The patients
with diabetes and strict administration of insulin during
the experiment only marginally differed from healthy
controls with respect to the plasma glucose concentra-
tion while their plasma insulin concentration was signifi-
cantly higher. These two groups did not differ at
baseline in other respects. Therefore, we propose that
the higher circulating insulin contributes to the observed
tolerance to forearm IR in this group. This conclusion is
supported by a large body of preclinical evidence indi-
cating a protective effect of insulin against IR-induced
cell death [35-37]. Based on this preclinical evidence, we
expected an increased targeting of annexin A5 after is-
chemic exercise in the patients with T1DM who were
studied during hyperglycemic conditions. This, however,
was not observed. We postulate that this is because the
protective effect of chronic insulin treatment was still
present after skipping one dose of insulin and remained
effective during the experiments.
Despite this reduced susceptibility for IR-injury, add-
itional protection by ischemic preconditioning was much
less effective in patients with T1DM than in healthy con-
trol subjects. In more detail, this protective effect was
small, and only observed in patients during normogly-
cemic conditions. During hyperglycemia, ischemic precon-
ditioning did not reduce annexin A5 targeting at all. In the
patients who were studied during hyperglycemia, the
plasma insulin concentration did not differ from that
observed in healthy volunteers. Therefore, it is unlikely
that insulin affected the protective effect of precondition-
ing in these patients, and it is more likely that the hyper-
glycemia abolished this protective effect. This is supported
by previous preclinical observations in animals using myo-
cardial infarct size as an endpoint [30,38] and it is consist-
ent with epidemiological evidence in humans [39]. A
possible explanation for this phenomenon is an acute im-
pairment of mitochondrial KATP-channels in response to
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hyperglycemia [38]. The patients who were studied during
hyperglycemia were significantly older than the healthy
volunteers and the patients who were studied during
normoglycemia. Advanced age has been associated with a
reduced efficacy of ischemic preconditioning to protect
against ischemic cell death [9]. However, the interaction
between ischemic preconditioning and experimental con-
dition remained when age was incorporated as a covariate
in the analysis of variance, excluding that age is a signifi-
cant confounder.
Taken together, these data provide human experimen-
tal evidence for aggressive normalization of plasma glu-
cose in patients with T1DM who experience repeated
bouts of ischemia, such as angina pectoris or transient
ischemic attacks, in order to optimize benefit from en-
dogenous protection by ischemic preconditioning. These
observations fit well with clinical data suggesting benefit
from insulin treatment in critically ill patients with a dis-
turbed tissue perfusion [40].
There are several limitations of our study. Since target-
ing of annexin A5 after forearm IR was low in patients
with diabetes, the potential window of protection by is-
chemic preconditioning was smaller. This could have
affected the power of our study to detect an effect of is-
chemic preconditioning in these patients. Indeed, in the
patients who were studied in normoglycemic conditions,
ischemic preconditioning tended to reduce targeting: in
6 out of 8 volunteers targeting was reduced (p = 0.087).
Our failure to detect a significant protection by ischemic
preconditioning in this group of patients might therefore
result from a lack of power due to reduced targeting at
baseline. Despite this small window of opportunity to
further reduce annexin A5 targeting, in the patients with
type 1 diabetes the effect of ischemic preconditioning
was significantly affected by the experimental condition
(hyperglycemic/normoinsulinemic or normoglycemic/
hyperinsulinemic), consistent with a direct effect of
hyperglycemia on the efficacy of ischemic precondition-
ing to prevent targeting of annexin A5. Secondly, since
we did not use a hyperinsulinemic clamp technique,
serum glucose levels tended to increase in the normogly-
cemic group during the last hours of the reperfusion
period. Furthermore, our experimental design resulted
in differences in both serum glucose and insulin between
the two groups of patients with diabetes, complicating
the interpretation of the study. However, the current de-
sign was chosen to allow an optimal comparison be-
tween the healthy volunteers and the normoinsulinemic
hyperglycemic patients with diabetes.
Conclusions
In conclusion, our data indicate that patients with T1DM
who are well controlled with chronic insulin treatment ap-
pear to be less vulnerable to IR-injury in our experimental
model compared to healthy control subjects. Most prob-
ably, this is caused by the higher plasma insulin concentra-
tion, which induces protection. In addition, hyperglycemia
abolishes the protective effect of ischemic preconditioning
on IR-injury. Taken together, these findings provide ex-
perimental evidence in humans to support aggressive
normalization of plasma glucose using insulin in patients
with T1DM who experience repeated bouts of ischemia, in
order to optimize benefit from insulin-induced protection
and endogenous protection by ischemic preconditioning.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
RE participated in the design of the study, carried out the study, performed
the analyses, and drafted the manuscript. NPR participated in the analyses of
the results, and drafted the manuscript. MJM and BB helped in the patient
recruitment and critically reviewed the manuscript. PM participated in
performing the experiments. OCB and WJGO performed the analyses of the
nuclear studies and critically reviewed the manuscript. PS, GAR, and CT
participated in the design of the study and critical review of the manuscript.
All authors read and approved the final manuscript.
Acknowledgements
The authors thank the research staff of the Clinical Research Centre
Nijmegen for their assistance in the performance of the experiments. This
work was supported by the Dutch Diabetes Foundation. NP Riksen is a
recipient of a Clinical Fellowship of the Netherlands Organisation for Health
Research and Development (ZonMw) and of a Dekker Fellowship of the
Dutch Heart Foundation.
Author details
1Department of Pharmacology-Toxicology, Radboud University Nijmegen
Medical Centre, P.O. Box 9101, Nijmegen 6500 HB, The Netherlands. 2General
Internal Medicine, Nijmegen, The Netherlands. 3Nuclear Medicine, Nijmegen,
The Netherlands. 4Department of Anesthesiology, Radboud University
Nijmegen Medical Centre, Nijmegen, The Netherlands. 5Slingeland Hospital,
Doetinchem, Netherlands. 6Canisius Wilhelmina Hospital, Nijmegen, The
Netherlands. 7Catharina Hospital, Eindhoven, the Netherlands.
Received: 28 August 2012 Accepted: 9 October 2012
Published: 10 October 2012
References
1. Orchard TJ, Costacou T, Kretowski A, Nesto RW: Type 1 diabetes and
coronary artery disease. Diabetes Care 2006, 29:2528–2538.
2. Mathew V, Gersh BJ, Williams BA, Laskey WK, Willerson JT, Tilbury RT, Davis
BR, Holmes DR Jr: Outcomes in patients with diabetes mellitus
undergoing percutaneous coronary intervention in the current era: a
report from the Prevention of REStenosis with Tranilast and its
Outcomes (PRESTO) trial. Circulation 2004, 109:476–480.
3. Donahoe SM, Stewart GC, McCabe CH, Mohanavelu S, Murphy SA, Cannon
CP, Antman EM: Diabetes and mortality following acute coronary
syndromes. JAMA 2007, 298:765–775.
4. Thourani VH, Weintraub WS, Stein B, Gebhart SS, Craver JM, Jones EL,
Guyton RA: Influence of diabetes mellitus on early and late outcome
after coronary artery bypass grafting. Ann Thorac Surg 1999,
67:1045–1052.
5. van Straten AH, Soliman Hamad MA, van Zundert AA, Martens EJ,
Schonberger JP, ter Woorst JF, de Wolf AM: Diabetes and survival after
coronary artery bypass grafting: comparison with an age- and sex-
matched population. Eur J Cardiothorac Surg 2010, 37:1068–1074.
6. Lind M, Bounias I, Olsson M, Gudbjornsdottir S, Svensson AM, Rosengren A:
Glycaemic control and incidence of heart failure in 20,985 patients with
type 1 diabetes: an observational study. Lancet 2011, 378:140–146.
Engbersen et al. Cardiovascular Diabetology 2012, 11:124 Page 6 of 7
http://www.cardiab.com/content/11/1/124
7. Murry CE, Jennings RB, Reimer KA: Preconditioning with ischemia: a
delay of lethal cell injury in ischemic myocardium. Circulation 1986,
74:1124–1136.
8. Riksen NP, Smits P, Rongen GA: Ischaemic preconditioning: from
molecular characterization to clinical application. Part II. Neth J Med 2004,
62:409–423.
9. Ferdinandy P, Schulz R, Baxter GF: Interaction of cardiovascular risk factors
with myocardial ischemia/reperfusion injury, preconditioning, and
postconditioning. Pharmacol Rev 2007, 59:418–458.
10. Whittington HJ, Babu GG, Mocanu MM, Yellon DM, Hausenloy DJ: The
diabetic heart: too sweet for its own good? Cardiol Res Pract 2012,
2012:845698.
11. Rongen GA, Oyen WJG, Ramakers BP, Riksen NP, Boerman OC, Steinmetz N,
Smits P: Annexin A5 scintigraphy of forearm as a novel in vivo model of
skeletal muscle preconditioning in humans. Circulation 2005, 111:173–178.
12. Riksen NP, Zhou Z, Oyen WJ, Jaspers R, Ramakers BP, Brouwer RM, Boerman
OC, Steinmetz N, Smits P, Rongen GA: Caffeine prevents protection in two
human models of ischemic preconditioning. J Am Coll Cardiol 2006,
48:700–707.
13. Riksen NP, Franke B, Oyen WJ, Borm GF, van den Broek P, Boerman OC,
Smits P, Rongen GA: Augmented hyperaemia and reduced tissue injury
in response to ischaemia in subjects with the 34C> T variant of the
AMPD1 gene. Eur Heart J 2007, 28:1085–1091.
14. Meijer P, Oyen WJ, Dekker D, Van den Broek PH, Wouters CW, Boerman OC,
Scheffer GJ, Smits P, Rongen GA: Rosuvastatin increases extracellular
adenosine formation in humans in vivo: a new perspective on
cardiovascular protection. Arterioscler Thromb Vasc Biol 2009, 29:963–968.
15. Wouters CW, Meijer P, Janssen CI, Frederix GW, Oyen WJ, Boerman OC,
Smits P, Rongen GA: Atorvastatin does not affect ischaemia-induced
phosphatidylserine exposition in humans in-vivo. J Atheroscler Thromb
2012, 19:285–291.
16. Koopman G, Reutelingsperger CP, Kuijten GA, Keehnen RM, Pals ST, van
Oers MH: Annexin V for flow cytometric detection of phosphatidylserine
expression on B cells undergoing apoptosis. Blood 1994, 84:1415–1420.
17. Schreiber-Deturmeny E, Bruguerolle B: Simultaneous high-performance
liquid chromatographic determination of caffeine and theophylline for
routine drug monitoring in human plasma. J Chromatogr B Biomed Appl
1996, 677:305–312.
18. Yellon DM, Hausenloy DJ: Myocardial reperfusion injury. N Engl J Med
2007, 357:1121–1135.
19. Hausenloy DJ, Mwamure PK, Venugopal V, Harris J, Barnard M, Grundy E,
Ashley E, Vichare S, Di SC, Kolvekar S, Hayward M, Keogh B, MacAllister RJ,
Yellon DM: Effect of remote ischaemic preconditioning on myocardial
injury in patients undergoing coronary artery bypass graft surgery: a
randomised controlled trial. Lancet 2007, 370:575–579.
20. Marso SP, Miller T, Rutherford BD, Gibbons RJ, Qureshi M, Kalynych A, Turco
M, Schultheiss HP, Mehran R, Krucoff MW, Lansky AJ, Stone GW:
Comparison of myocardial reperfusion in patients undergoing
percutaneous coronary intervention in ST-segment elevation acute
myocardial infarction with versus without diabetes mellitus (from the
EMERALD Trial). Am J Cardiol 2007, 100:206–210.
21. Alegria JR, Miller TD, Gibbons RJ, Yi QL, Yusuf S: Infarct size, ejection
fraction, and mortality in diabetic patients with acute myocardial
infarction treated with thrombolytic therapy. Am Heart J 2007,
154:743–750.
22. Rodrigues B, Rosa KT, Medeiros A, Schaan BD, Brum PC, De AK, Irigoyen MC:
Hyperglycemia can delay left ventricular dysfunction but not autonomic
damage after myocardial infarction in rodents. Cardiovasc Diabetol 2011,
10:26.
23. Paulson DJ: The diabetic heart is more sensitive to ischemic injury.
Cardiovasc Res 1997, 34:104–112.
24. Balakumar P, Sharma NK: Healing the diabetic heart: does myocardial
preconditioning work? Cell Signal 2012, 24:53–59.
25. Feuvray D, Lopaschuk GD: Controversies on the sensitivity of the diabetic
heart to ischemic injury: the sensitivity of the diabetic heart to ischemic
injury is decreased. Cardiovasc Res 1997, 34:113–120.
26. Miki T, Itoh T, Sunaga D, Miura T: Effects of diabetes on myocardial infarct
size and cardioprotection by preconditioning and postconditioning.
Cardiovasc Diabetol 2012, 11:67.
27. Van der Mieren G, Nevelsteen I, Vanderper A, Oosterlinck W, Flameng W,
Herijgers P: Angiotensin-converting enzyme inhibition and food
restriction in diabetic mice do not correct the increased sensitivity for
ischemia-reperfusion injury. Cardiovasc Diabetol 2012, 11:89.
28. Kersten JR, Toller WG, Gross ER, Pagel PS, Warltier DC: Diabetes abolishes
ischemic preconditioning: role of glucose, insulin, and osmolality. Am J
Physiol Heart Circ Physiol 2000, 278:H1218–H1224.
29. del Valle HF, Lascano EC, Negroni JA, Crottogini AJ: Absence of ischemic
preconditioning protection in diabetic sheep hearts: role of sarcolemmal
KATP channel dysfunction. Mol Cell Biochem 2003, 249:21–30.
30. Kersten JR, Schmeling TJ, Orth KG, Pagel PS, Warltier DC: Acute
hyperglycemia abolishes ischemic preconditioning in vivo. Am J Physiol
1998, 275:H721–H725.
31. Tsang A, Hausenloy DJ, Mocanu MM, Carr RD, Yellon DM: Preconditioning
the diabetic heart: the importance of Akt phosphorylation. Diabetes 2005,
54:2360–2364.
32. Ghosh S, Standen NB, Galinianes M: Failure to precondition pathological
human myocardium. J Am Coll Cardiol 2001, 37:711–718.
33. Hassouna A, Loubani M, Matata BM, Fowler A, Standen NB, Galinanes M:
Mitochondrial dysfunction as the cause of the failure to precondition
the diabetic human myocardium. Cardiovasc Res 2006, 69:450–458.
34. Sivaraman V, Hausenloy DJ, Wynne AM, Yellon DM: Preconditioning the
diabetic human myocardium. J Cell Mol Med 2010, 14:1740–1746.
35. Jonassen AK, Brar BK, Mjos OD, Sack MN, Latchman DS, Yellon DM: Insulin
administered at reoxygenation exerts a cardioprotective effect in
myocytes by a possible anti-apoptotic mechanism. J Mol Cell Cardiol
2000, 32:757–764.
36. Melin J, Hellberg O, Larsson E, Zezina L, Fellstrom BC: Protective effect of
insulin on ischemic renal injury in diabetes mellitus. Kidney Int 2002,
61:1383–1392.
37. Sack MN, Yellon DM: Insulin therapy as an adjunct to reperfusion after
acute coronary ischemia: a proposed direct myocardial cell survival
effect independent of metabolic modulation. J Am Coll Cardiol 2003,
41:1404–1407.
38. Kersten JR, Montgomery MW, Ghassemi T, Gross ER, Toller WG, Pagel PS,
Warltier DC: Diabetes and hyperglycemia impair activation of
mitochondrial K(ATP) channels. Am J Physiol Heart Circ Physiol 2001, 280:
H1744–H1750.
39. Ishihara M, Inoue I, Kawagoe T, Shimatani Y, Kurisu S, Nishioka K, Umemura
T, Nakamura S, Yoshida M: Effect of acute hyperglycemia on the ischemic
preconditioning effect of prodromal angina pectoris in patients with a
first anterior wall acute myocardial infarction. Am J Cardiol 2003,
92:288–291.
40. Wade AO, Cordingley JJ: Glycaemic control in critically ill patients with
cardiovascular disease. Curr Opin Crit Care 2006, 12:437–443.
doi:10.1186/1475-2840-11-124
Cite this article as: Engbersen et al.: Improved resistance to ischemia
and reperfusion, but impaired protection by ischemic preconditioning
in patients with type 1 diabetes mellitus: a pilot study. Cardiovascular
Diabetology 2012 11:124.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Engbersen et al. Cardiovascular Diabetology 2012, 11:124 Page 7 of 7
http://www.cardiab.com/content/11/1/124
